1 Tracleer® - Summary of Product Characteristics.
2 Rubin LJ, Badesch DB, Barst RG, et al.  Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med 2002; 346(12): 896-903.
3 Channick RN, Simonneau G, Sitbon O, et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet 2001; 358(9288): 1119-1123.
Keogh A, Wlodarczyk J. Idiopathic and scleroderma-related pulmonary arterial hypertension: outcome and QoL on bosentan. Expert Rev Pharmacoeconomics Outcomes Res 2004;4;505-513.
4 Simonneau et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:Suppl S: 5S-12S
5 D'Alonzo GE, Barst RJ, Ayres SMet al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115(5): 343-349.
6 Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 40S-47S. Related Articles, Links. 
7 KatoI, Severson RK, Schwartz AG. Conditional median survival in patients with advanced carcinoma. Cancer 2001;92:2211-19.
8 Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
9 McGoon M, Gutterman D, Steen V et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl): 14S-34S.
10 Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol (1996);35(10):989-993
11 Galiè N, Torbicki A, Barst RJ et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-78
12 Speich R, Jenni R, Opravil M et al. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-71
13 Pietra GG, Capron F, Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 25S-32S.
14 Pietra GG, Edwards WD, Kay JM et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80(5): 1198-1206.
15 Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000;49:485-92
16 Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-415.
17 Humbert M, Morrell NW, Archer SL et al. Cellular and Molecular Pathobiology of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004;43:13S–24S
18 Clozel M, Gray GA, Breu V et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186(2): 867-873.
19 Hocher B, George I, Rebstock J et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33(3): 816-822.
20 Seo B, Oemar BS, Siebenmann R et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89(3): 1203-1208.
21 Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61(2): 227-237.
22 Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995;26:S262-4.
23 Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114(6): 464-469.
24 Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21(10): 1838-1844.
25 Yoshibayashi M, Nishioka K, Nakao K et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84(6): 2280-2285. Related Articles, Links 
26 Galiè N, Grigioni F, Bacchi-Reggiani et al. Relation of endothelin-1 to survival in patients with primary pulmomnary hypertension. Eur J Clin Invest 1996; 26: 273.
27 Humbert M, Sitbon O, Chaouat A et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. Am J Respir Crit Care Med 2006; 173(9): 1023-1030.
28 Anon. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1): 111-117.
29 Sitbon O, Humbert M, Jaïs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary hypertension. Circulation 2005; 111:3105-3111
30 Clozel M, Breu V, Gray GA et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270(1): 228-235.
31 Girgis RE, Champion HC, Diette GB et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005; 172(3): 352-357.
32 Filep JG, Fournier A, Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol 1995; 115(2): 227-236.
33 Xu Shi-wen, Christopher P Denton, Michael R Dashwood et al. Fibroblast Matrix Gene Expression and Connective Tissue Remodeling: Role of Endothelin-1. J Invest Dermatol 2001; 116: 417-425. [free citation available – please click here]
34 Badesch DB, Abman SH, Ahearn GS et al; American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl): 35S-62S. [free citation available – please click here]
35 Galie N, Hinderliter AL, Torbicki A et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(8): 1380-1386.
36 Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J respir Crit Care Med 2000;161:487-492.
37 Sitbon O, Badesch DB, Channick RN et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124(1): 247-254. [free citation available – please click here]
38 McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25(2): 244-249.
39 Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: Improved survival in the current ERA. Heart.doi.1136/hrt.2005.069484
40 Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60:1025–30.
41 Opravil M, Pechere M, Sp eich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155(3): 990-995.
42 Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170(11): 1212-1217.
43 Barst RJ, Ivy D, Dingemanse J, Widlitz A et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73(4): 372-382.
44 Humbert M et al. ATS 2005: A300.